Pepstatin A

Catalog No.S7381 Synonyms: Pepstatin

For research use only.

Pepstatin A (Pepstatin) is a potent aspartic protease inhibitor, and also inhibits HIV replication. Pepstatin A is also an inhibitor of cathepsins D and cathepsins E. Pepstatin A inhibits autophagy by suppressing lysosomal proteases.

Pepstatin A Chemical Structure

CAS No. 26305-03-3

Selleck's Pepstatin A has been cited by 20 publications

Purity & Quality Control

Choose Selective HIV Protease Inhibitors

Other HIV Protease Products

Biological Activity

Description Pepstatin A (Pepstatin) is a potent aspartic protease inhibitor, and also inhibits HIV replication. Pepstatin A is also an inhibitor of cathepsins D and cathepsins E. Pepstatin A inhibits autophagy by suppressing lysosomal proteases.
Targets
aspartic protease [1] cathepsins D [2] cathepsins E [2]
In vitro

Pepstatin A shows effective inhibition on aspartic proteinases such as pepsin, cathepsins D and E. In HIV-infected H9 cells, pepstatin A inhibits part of the intracellular processing of the HIV gag protein with no apparent toxicity on HIV-infected cells. [1] Pepstatin A laos suppresses the differentiation of osteoclasts by blocking ERK signaling and the inhibition of NFATc1 expression. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDA-MB-231 Mn;rSpVv[3Srb36gZZN{[Xl? MVmzJIRigXN? NInI[YhKdmirYnn0bY9vKG:oIIPlZ5JmfGWmIHPheIhmeHOrbjDEJIlvKGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgeZNqdmdiTXPhMWdtgS2OeYOtVJJwNUmuZT3M[ZUuWGinUHjlMWFz\y2OZYWtUJl{NSiGboCpMWQuSXKpLV7INkBieyC|dXLzeJJifGVicILleJJm[XSnZDDmc5IhOyCmYYnzJJVv\GW{IIDIJFYvPiClb37kbZRqd26nZDDt[YRq[SCob3zsc5dm\CCkeTDzeYJ{fHKjdHWgZYRlcXSrb36gcYVie3W{ZXSgZZQhPSCvaX7zJIlvfGW{dnHsJIZweiBuIFnDOVA:OC5yMECx{txONg>? M1PwUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MEi3O|EzLz5{OUC4O|cyOjxxYU6=
MDA-MB-231 M2K5R2Z2dmO2aX;uJIF{e2G7 MUGzJIRigXN? M4T3TGlvcGmkaYTpc44hd2Zic3XjdoV1\WRiY3H0bIVxe2mwIFWgbY4hcHWvYX6gUWRCNU2ELUKzNUBk\WyuczD1d4lv\yCPY3GtS4x6NUy7cz3Qdo8uUWynLVzleU1RcGWSaHWtRZJoNUyndT3MfZMuMESwcDmtSE1CemdvTliyJIF{KHO3YoP0doF1\SCycnX0doVifGWmIH\vdkA{KGSjeYOgeY5l\XJicFigOk43KGOxbnTpeIlwdmWmIH3l[IliKG[xbHzve4VlKGK7IIP1ZpN1emG2ZTDh[IRqfGmxbjDt[YF{fXKnZDDheEA2KG2rboOgbY51\XK4YXyg[o9zKCxiSVO1NF0xNjByMEJOwG0v MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTB6N{exNkc,OjlyOEe3NVI9N2F-
MCF7 Mn2wSpVv[3Srb36gZZN{[Xl? NILrXo1KdmirYnn0bY9vKG:oIHPheIhmeHOrbjDEJIlvKGi3bXHuJG1ETjdiY3XscJMh[nliZnz1c5Jme2OnbnPlJIF{e2G7LDDJR|UxRTBwMEC1{txONg>? M33nTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{G1N|IxLz5zOUexOVMzODxxYU6=
MCF7 Mnz3SpVv[3Srb36gZZN{[Xl? MYXJcohq[mm2aX;uJI9nKGOjdHjldJNqdiCHIHnuJIh2dWGwIF3DSlch[2WubIOgZpkh\my3b4Lld4NmdmOnIHHzd4F6NCCLQ{WwQVAvODB3zszNMi=> NHzFV|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUexOVMzOCd-MUm3NVU{OjB:L3G+
MDA-MB-231 NF7mRXlHfW6ldHnvckBie3OjeR?= NIPCeJA1KGi{cx?= MWHJcohq[mm2aX;uJI9nKGOjdHjldJNqdiCGIHnuJIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNidYPpcochVWOjLVfsfU1NgXNvUILvMWlt\S2OZYWtVIhmWGinLVHy[{1N\XVvTInzMUhFdnBrLVStRZJoNU6KMjDhd{B{fWK|dILheIUheHKndILlZZRm\CCob4KgOEBpenNiZn;scI94\WRiYomgZ49ueG:3bnSge4F{cG:3dDDhcoQhe3Wkc3XxeYVvfCC|dXLzeJJifGViYXTkbZRqd25ibXXhd5Vz\WRiYYSgN|Ahe2WlczDpcpRmen[jbDDmc5IhOzBibXnud{AtKEmFNUC9NE4y|ryPLh?= NXv6UYdrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmwPFc4OTJpPkK5NFg4PzF{PD;hQi=>
MDA-MB-231 MlfmSpVv[3Srb36gZZN{[Xl? NULFbWtPPCCqcoO= NXfNeXpHUW6qaXLpeIlwdiCxZjDjZZRp\XC|aX6gSUBqdiCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJJV{cW6pIF3jZU1IdHlvTInzMXBzdy2LbHWtUIV2NVCqZWDo[U1CemdvTHX1MWx6ey1qRH7wLU1FNUG{Zz3OTFIh[XNic4Xid5Rz[XSnIIDy[ZRz\WG2ZXSg[o9zKDRiaILzJIZwdGyxd3XkJIJ6KGOxbYDveY5lKHejc3jveZQh[W6mIIP1ZpNmeXWnboSgd5Vje3S{YYTlJIFl\Gm2aX;uJI1m[XO3cnXkJIF1KDNyIIPlZ5MhcW62ZYL2ZYwh\m:{IEOwJI1qdnNiLDDJR|UxRTBwMd88UU4> MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTB6N{exNkc,OjlyOEe3NVI9N2F-
MDA-MB-231 NFj2[|JHfW6ldHnvckBie3OjeR?= NI\JfIg1KGi{cx?= MV7Jcohq[mm2aX;uJI9nKGOjdHjldJNqdiCGIHnuJIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNidYPpcochVWOjLVfsfU1NgXNvUILvMWlt\S2OZYWtVIhmWGinLVHy[{1N\XVvTInzMUhFdnBrLVStRZJoNU6KMjDhd{B{fWK|dILheIUheHKndILlZZRm\CCob4KgOEBpenNiZn;scI94\WRiYomgZ49ueG:3bnSge4F{cG:3dDDhcoQhe3Wkc3XxeYVvfCBzMDDtbY5{KHS{eYDzbY5qgmG2aX;uJJBzcW:{IITvJJN2[nO2cnH0[UBi\GSrdHnvckBu\WG|dYLl[EAtKEmFNUC9Ne69VS5? M2fpbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MEi3O|EzLz5{OUC4O|cyOjxxYU6=
MDA-MB-231 NEO2W3ZHfW6ldHnvckBie3OjeR?= M1W5fVQhcHK| NUjvfXdpUW6qaXLpeIlwdiCxZjDjZZRp\XC|aX6gSUBqdiCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJJV{cW6pIF3jZU1IdHlvTInzMXBzdy2LbHWtUIV2NVCqZWDo[U1CemdvTHX1MWx6ey1qRH7wLU1FNUG{Zz3OTFIh[XNic4Xid5Rz[XSnIIDy[ZRz\WG2ZXSg[o9zKDRiaILzJIZwdGyxd3XkJIJ6KGOxbYDveY5lKHejc3jveZQh[W6mIIP1ZpNmeXWnboSgNVAhdWmwczD0dplxe2mwaYrheIlwdiCycnnvdkB1dyC|dXLzeJJifGViYXTkbZRqd25ibXXhd5Vz\WRiLDDJR|UxRTIQvF2u MlnLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlyOEe3NVIoRjJ7MEi3O|EzRC:jPh?=
MCF7 MkPqSpVv[3Srb36gZZN{[Xl? NHjPfGUyKGi{ NYfOVXJ{UW6qaXLpeIlwdiCxZjDjZZRp\XC|aX6gSEBqdiCqdX3hckBOS0Z5IHPlcIx{KHS{ZXH0[YQh\m:{IEGgbJIhdWWjc4Xy[YQh[W[2ZYKge4F{cG:3dDDhcoQhfHK7cIPpckB1emWjdH3lcpQh[nliZnz1c5Jme2OnbnPlJIF{e2G7LDDJR|UxRTYQvF2u NX7JSW85RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3NVU{OjBpPkG5O|E2OzJyPD;hQi=>
MCF7 NX7j[nlMTnWwY4Tpc44h[XO|YYm= NFvCfokyKGi{ M3HPfmlvcGmkaYTpc44hd2ZiY3H0bIVxe2mwIFWgbY4hcHWvYX6gUWNHPyClZXzsd{B1emWjdHXkJIZweiBzIHjyJI1m[XO3cnXkJIFnfGW{IIfhd4hwfXRiYX7kJJRzgXC|aX6geJJm[XSvZX70JIJ6KG[udX;y[ZNk\W6lZTDhd5NigSxiSVO1NF02|ryPLh?= MnLFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5MUWzNlAoRjF7N{G1N|IxRC:jPh?=
NB1643 M{XLe5FJXFNiYYPzZZk> M3LafpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG5DOTZ2MzDj[Yxtew>? Mn65QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
A673 NEC4elZyUFSVIHHzd4F6 NYTnXoU2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSTZ5MzDj[Yxteyl? MojjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC Mn\CdWhVWyCjc4PhfS=> MXvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNU2FIHPlcIx{ MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
TC32 NGjke4xyUFSVIHHzd4F6 MlnsdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWGM{OiClZXzsdy=> MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 685.89
Formula

C34H63N5O9

CAS No. 26305-03-3
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(C)CC(C(CC(=O)O)O)NC(=O)C(C)NC(=O)CC(C(CC(C)C)NC(=O)C(C(C)C)NC(=O)C(C(C)C)NC(=O)CC(C)C)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
Do you have recommended in-vivo solvent for S7381 please?

Answer:
S7381 could be dissolved in 5%DMSO+40%PEG300+5%tween-80+ddH2O up to 2mg/ml.

Tags: buy Pepstatin A | Pepstatin A supplier | purchase Pepstatin A | Pepstatin A cost | Pepstatin A manufacturer | order Pepstatin A | Pepstatin A distributor